Denali Therapeutics Inc’s filing revealed that its Chief Medical Officer Ho Carole unloaded Company’s shares for reported $0.25 million on Jan 06 ’25. In the deal valued at $20.22 per share,12,255 shares were sold. As a result of this transaction, Ho Carole now holds 178,580 shares worth roughly $4.2 million.
Then, Ho Carole sold 2,907 shares, generating $60,495 in total proceeds. Upon selling the shares at $20.81, the Chief Medical Officer now owns 175,673 shares.
Before that, Schuth Alexander O. sold 12,255 shares. Denali Therapeutics Inc shares valued at $247,796 were divested by the COFO and Secretary at a price of $20.22 per share. As a result of the transaction, Schuth Alexander O. now holds 247,215 shares, worth roughly $5.81 million.
Robert W. Baird initiated its Denali Therapeutics Inc [DNLI] rating to an Outperform in a research note published on January 07, 2025; the price target was $31. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in early January with a ‘”an Outperform”‘ rating. Stifel also remained covering DNLI and has increased its forecast on December 16, 2024 with a “Buy” recommendation from previously “Hold” rating.
Price Performance Review of DNLI
On Tuesday, Denali Therapeutics Inc [NASDAQ:DNLI] saw its stock jump 1.34% to $23.50. Over the last five days, the stock has gained 2.00%. Denali Therapeutics Inc shares have risen nearly 15.31% since the year began. Nevertheless, the stocks have risen 36.63% over the past one year. While a 52-week high of $33.33 was reached on 01/22/25, a 52-week low of $14.56 was recorded on 01/14/25. SMA at 50 days reached $22.92, while 200 days put it at $23.23.
Levels Of Support And Resistance For DNLI Stock
The 24-hour chart illustrates a support level at 22.85, which if violated will result in even more drops to 22.21. On the upside, there is a resistance level at 23.83. A further resistance level may holdings at 24.17. The Relative Strength Index (RSI) on the 14-day chart is 57.15, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.29, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 3.68%. Stochastics %K at 86.07% indicates the stock is a selling.
How much short interest is there in Denali Therapeutics Inc?
A steep rise in short interest was recorded in Denali Therapeutics Inc stocks on 2025-01-15, growing by 0.5 million shares to a total of 7.97 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 7.46 million shares. There was a rise of 6.34%, which implies that there is a positive sentiment for the stock.
